# Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

Study · id `cardio:ct-nct06579105` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06579105](<https://clinicaltrials.gov/study/NCT06579105>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06579105

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 406 participants.

## Technical summary

Registry record NCT06579105. Randomized; triple masking; primary purpose treatment. Start 2024-10-08 (actual); primary completion 2025-12-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 406 participants (enrolled count; ClinicalTrials.gov record NCT06579105, source copy `cardio:ctgov-nct06579105-2026-01-13`, retrieved 2026-10-26)
- Started: 2024-10-08 (actual) (ClinicalTrials.gov record NCT06579105, source copy `cardio:ctgov-nct06579105-2026-01-13`, retrieved 2026-10-26)
- Primary completion: 2025-12-19 (actual) (ClinicalTrials.gov record NCT06579105, source copy `cardio:ctgov-nct06579105-2026-01-13`, retrieved 2026-10-26)
- Completion: 2025-12-19 (actual) (ClinicalTrials.gov record NCT06579105, source copy `cardio:ctgov-nct06579105-2026-01-13`, retrieved 2026-10-26)
- Countries: United States; Canada; Germany; Hungary; Japan; Poland; Slovakia; Spain; United Kingdom (ClinicalTrials.gov record NCT06579105, source copy `cardio:ctgov-nct06579105-2026-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06579105-2026-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
- Acronym: SOLSTICE
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Placebo (placebo matching AZD5004 film-coated tablet)
- Intervention (Drug): AZD5004
- Intervention (Drug): Semaglutide
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial (`cardio:pubmed-42259343`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2a6b6800f8eba6435bce22124ff5ddecdfb9485af1ef4844682a30e4b2a6940b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
